OSCR Quote, Financials, Valuation and Earnings

Clover Health Investments has a net margin of 9.04% compared to Oscar Health's net margin of -0.28%. Oscar Health's return on equity of 10.83% beat Clover Health Investments's return on equity of -7.67%.

Oscar Health has a consensus price target of $17.49, signalling downside risk potential of -14.29%. On the other hand Clover Health Investments has an analysts' consensus of $4.69 which suggests that it could grow by 69.84%. Given that Clover Health Investments has higher upside potential than Oscar Health, analysts believe Clover Health Investments is more attractive than Oscar Health.

Oscar Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Clover Health Investments has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Oscar Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clover Health Investments offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oscar Health pays -- of its earnings as a dividend. Clover Health Investments pays out -- of its earnings as a dividend.

Oscar Health quarterly revenues are $3B, which are larger than Clover Health Investments quarterly revenues of $462.3M. Oscar Health's net income of $275.3M is higher than Clover Health Investments's net income of -$1.3M. Notably, Oscar Health's price-to-earnings ratio is 72.89x while Clover Health Investments's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oscar Health is 0.56x versus 0.92x for Clover Health Investments. Usually stocks with elevated PS ratios are considered overvalued.

NeueHealth has a net margin of 9.04% compared to Oscar Health's net margin of -5.44%. Oscar Health's return on equity of 10.83% beat NeueHealth's return on equity of -3241.93%.

Oscar Health has a consensus price target of $17.49, signalling downside risk potential of -14.29%. On the other hand NeueHealth has an analysts' consensus of $7.00 which suggests that it could grow by 0.87%. Given that NeueHealth has higher upside potential than Oscar Health, analysts believe NeueHealth is more attractive than Oscar Health.

Oscar Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NeueHealth has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Oscar Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeueHealth offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oscar Health pays -- of its earnings as a dividend. NeueHealth pays out -- of its earnings as a dividend.

Oscar Health quarterly revenues are $3B, which are larger than NeueHealth quarterly revenues of $215.8M. Oscar Health's net income of $275.3M is higher than NeueHealth's net income of -$11.7M. Notably, Oscar Health's price-to-earnings ratio is 72.89x while NeueHealth's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oscar Health is 0.56x versus 0.06x for NeueHealth. Usually stocks with elevated PS ratios are considered overvalued.

Progyny has a net margin of 9.04% compared to Oscar Health's net margin of 4.65%. Oscar Health's return on equity of 10.83% beat Progyny's return on equity of 11.16%.

Oscar Health has a consensus price target of $17.49, signalling downside risk potential of -14.29%. On the other hand Progyny has an analysts' consensus of $26.25 which suggests that it could grow by 19.81%. Given that Progyny has higher upside potential than Oscar Health, analysts believe Progyny is more attractive than Oscar Health.

Oscar Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Progyny has a beta of 1.317, suggesting its more volatile than the S&P 500 by 31.741%.

Oscar Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oscar Health pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

Oscar Health quarterly revenues are $3B, which are larger than Progyny quarterly revenues of $324M. Oscar Health's net income of $275.3M is higher than Progyny's net income of $15.1M. Notably, Oscar Health's price-to-earnings ratio is 72.89x while Progyny's PE ratio is 38.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oscar Health is 0.56x versus 1.70x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.

UnitedHealth Group has a net margin of 9.04% compared to Oscar Health's net margin of 5.74%. Oscar Health's return on equity of 10.83% beat UnitedHealth Group's return on equity of 21.74%.

Oscar Health has a consensus price target of $17.49, signalling downside risk potential of -14.29%. On the other hand UnitedHealth Group has an analysts' consensus of $385.25 which suggests that it could grow by 24.63%. Given that UnitedHealth Group has higher upside potential than Oscar Health, analysts believe UnitedHealth Group is more attractive than Oscar Health.

Oscar Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison UnitedHealth Group has a beta of 0.442, suggesting its less volatile than the S&P 500 by 55.841%.

Oscar Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group offers a yield of 2.75% to investors and pays a quarterly dividend of $2.21 per share. Oscar Health pays -- of its earnings as a dividend. UnitedHealth Group pays out 52.29% of its earnings as a dividend. UnitedHealth Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Oscar Health quarterly revenues are $3B, which are smaller than UnitedHealth Group quarterly revenues of $109.6B. Oscar Health's net income of $275.3M is lower than UnitedHealth Group's net income of $6.3B. Notably, Oscar Health's price-to-earnings ratio is 72.89x while UnitedHealth Group's PE ratio is 12.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oscar Health is 0.56x versus 0.70x for UnitedHealth Group. Usually stocks with elevated PS ratios are considered overvalued.